NYSE$HAE
Haemonetics Corp. · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Haemonetics reported first quarter fiscal 2022 results with increased guidance for vascular closure revenue and affirmed all other fiscal 2022 guidance, and expanded operational excellence program.
Haemonetics' first quarter fiscal 2022 performance showed a positive start to the year, driven by recovery across all businesses, especially Hospital, and initial Plasma Persona® rollouts. The company remains confident in strong end-market demand and anticipates full recovery from the pandemic by the end of the fiscal year. The revised Operational Excellence Program aims to enhance quality, service, and productivity, offsetting impacts from customer loss, the pandemic, and inflationary pressures.
- First quarter fiscal 2022 revenue increased by 17% to $229 million.
- Organic revenue growth was 16%.
- Adjusted earnings per diluted share were $0.50.
- The company is increasing guidance for Vascular Closure revenue and affirming all other fiscal 2022 guidance.
Headline financials
Revenue & EPS history
Haemonetics · Revenue · Quarterly
$229M
Revenue by segment
Haemonetics · $223M total across 3 segments · Q1 2022
- Hospital$78.5M+75.1%35.2%
- Blood Center$72.9M-6.2%32.7%
- Plasma$71.8M+5.3%32.2%
Forward guidance
The Company affirmed its GAAP total revenue growth guidance of 13 – 18% and organic revenue growth guidance issued on May 13, 2021.
Tailwinds
- Total revenue growth: 13-18%
- Plasma revenue growth: 15-25%
- Hospital revenue growth: 15-20%
- Adjusted operating margin: 19-20%
- Adjusted earnings per diluted share: $2.60 - $3.00
Headwinds
- Blood Center revenue growth: (6-8%)
- Impact of currency fluctuation
- Strategic exits of product lines
- Acquisitions and divestitures
- Impact of the 53rd week in fiscal 2021
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+1.4%
Avg return
Earnings day
+4.1%
Avg return
5 days after
+6.5%
Avg return
30 days after
56%
38 / 68 earnings
Positive
+31.8%
Q2 2026
Best reaction
-15.0%
Q4 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +3.3% | +2.5% | +35.5% | |
| Q3 2026 | -1.4% | -9.8% | -2.8% | |
| Q2 2026 | +31.8% | +41.4% | +65.5% | |
| Q4 2025 | +5.9% | +7.6% | +9.7% | |
| Q3 2025 | -11.6% | -13.6% | -3.6% | |
| Q2 2025 | +11.8% | +19.5% | +3.9% | |
| Q1 2025 | -10.1% | -13.4% | -14.6% | |
| Q4 2024 | +2.8% | +4.4% | -8.2% | |
| Q3 2024 | -3.8% | -7.0% | +3.2% | |
| Q2 2024 | +2.4% | +2.5% | -2.5% | |
| Q1 2024 | +2.0% | +3.0% | -0.8% | |
| Q4 2023 | +7.6% | +7.4% | +6.1% | |
| Q3 2023 | -5.4% | -8.2% | -12.2% | |
| Q2 2023 | +4.1% | -1.7% | +3.5% | |
| Q1 2023 | +8.1% | +12.3% | +13.7% | |
| Q4 2022 | +3.9% | +14.1% | +31.5% | |
| Q3 2022 | +21.2% | +24.5% | +18.9% | |
| Q2 2022 | -13.5% | -15.7% | -24.8% | |
| Q1 2022 | +8.4% | +1.8% | +16.8% | |
| Q4 2021 | -6.4% | -5.4% | +0.4% | |
| Q3 2021 | +12.8% | +21.1% | +4.0% | |
| Q2 2021 | -3.7% | +5.6% | +13.2% | |
| Q1 2021 | -12.7% | -8.5% | +3.3% | |
| Q4 2020 | -8.8% | -3.4% | -11.1% | |
| Q3 2020 | +7.2% | +7.7% | -7.3% | |
| Q2 2020 | +0.3% | +0.5% | -0.1% | |
| Q1 2020 | +10.5% | +13.5% | +10.8% | |
| Q4 2019 | +2.8% | +3.4% | +10.0% | |
| Q3 2019 | -12.2% | -14.3% | -13.0% | |
| Q2 2019 | +9.1% | +5.8% | -0.2% | |
| Q1 2019 | +4.8% | +2.7% | +14.4% | |
| Q4 2018 | +5.8% | +11.2% | +18.9% | |
| Q3 2018 | +14.8% | +13.1% | +20.5% | |
| Q2 2018 | +15.8% | +16.4% | +20.8% | |
| Q1 2018 | +4.2% | +3.2% | +3.9% | |
| Q4 2017 | -1.9% | -4.4% | -4.0% | |
| Q3 2017 | -10.1% | -9.0% | -7.3% | |
| Q2 2017 | +10.5% | +13.8% | +16.5% | |
| Q1 2017 | +13.8% | +16.8% | +22.6% | |
| Q4 2016 | -15.0% | — | — | |
| Q3 2016 | +5.9% | — | — | |
| Q2 2016 | -3.9% | — | — | |
| Q1 2016 | +1.5% | — | — | |
| Q4 2015 | -3.9% | — | — | |
| Q3 2015 | +7.0% | — | — | |
| Q2 2015 | -5.9% | — | — | |
| Q1 2015 | -1.4% | — | — | |
| Q4 2014 | -8.0% | — | — | |
| Q3 2014 | -2.6% | — | — | |
| Q2 2014 | +1.5% | — | — | |
| Q1 2014 | +0.7% | — | — | |
| Q4 2013 | -1.4% | — | — | |
| Q3 2013 | -5.6% | — | — | |
| Q2 2013 | +4.3% | — | — | |
| Q1 2013 | -0.1% | — | — | |
| Q4 2012 | +4.2% | — | — | |
| Q3 2012 | -1.0% | — | — | |
| Q2 2012 | +0.4% | — | — | |
| Q1 2012 | +3.1% | — | — | |
| Q4 2011 | +1.3% | — | — | |
| Q4 2009 | +1.3% | — | — | |
| Q3 2010 | -1.3% | — | — | |
| Q3 2011 | -1.3% | — | — | |
| Q2 2011 | +1.7% | — | — | |
| Q1 2010 | -2.5% | — | — | |
| Q2 2010 | -2.5% | — | — | |
| Q1 2011 | -2.5% | — | — | |
| Q4 2010 | -2.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro